胆道癌免疫疗法的现状及展望

罗奎; 孙航; 吴传新

doi:10.3969/j.issn.1001-5256.2019.12.043

胆道癌免疫疗法的现状及展望

DOI: 10.3969/j.issn.1001-5256.2019.12.043

重庆医科大学附属第二医院肝胆外科

基金项目:

国家自然科学基金面上项目(81871608)；

详细信息

中图分类号: R735.8
计量
- 文章访问数: 1219
- HTML全文浏览量: 56
- PDF下载量: 253
- 被引次数: 0
出版历程
- 收稿日期: 2019-08-10
- 出版日期: 2019-12-20

Immunotherapy for biliary tract cancer: Current status and perspectives

Department of Hepatobiliary Surgery,The Second Affiliated Hospital of Chongqing Medical University

Research funding:

摘要

摘要: 胆道癌在临床上较为少见,早期诊断困难,常规治疗手段疗效欠佳。作为时下新兴的研究热点,免疫疗法已被证实在多种癌症治疗中具备良好前景。目前包括免疫检查点抑制剂、过继免疫细胞治疗、肿瘤疫苗等在内的多种免疫疗法已经被运用于胆道癌的相关临床试验治疗中。现就免疫疗法在胆道癌治疗中的现状及展望进行简要阐述。
- 胆道肿瘤 /
- 免疫疗法 /
- 治疗学
Abstract: Biliary tract cancer( BTC) is rare in clinical practice and is difficult to diagnose in the early stage,and conventional treatment methods have unsatisfactory clinical effects. As a new research hotspot at present,immunotherapy has been proven to have a promising future in the treatment of a variety of cancers. At present,various immunotherapies,including immunological checkpoint inhibitors,adoptive immune cell therapy,and tumor vaccine therapy,have been applied in the clinical trials of BTC. This article briefly describes the current status and perspectives of immunotherapy in the treatment of BTC.
- biliary tract neoplasms /
- immunotherapy /
- therapeutics

HTML全文

参考文献(29)

[1] EBATA T,ERCOLANI G,ALVARO D,et al. Current status on cholangiocarcinoma and gallbladder cancer[J]. Liver Cancer,2016,6(1):59-65.

[2] FRANKLIN C,LIVINGSTONE E,ROESCH A,et al. Immunotherapy in melanoma:Recent advances and future directions[J]. Eur J Surg Oncol,2017,43(3):604-611.

[3] BEDKE J,STHLER V,STENZL A,et al. Immunotherapy for kidney cancer:Status quo and the future[J]. Curr Opin Urol,2018,28(1):8-14.

[4] JIN TQ,XU F,DAI CL. Research advances in immunotherapy for liver metastasis of pancreatic cancer[J]. J Clin Hepatol,2018,34(11):2469-2474.(in Chinese)金添强，徐锋，戴朝六．胰腺癌肝转移免疫治疗的研究进展[J]．临床肝胆病杂志，2018,34(11):2469-2474.

[5] MENG QH,TIAN J,QIN FZ,et al. Research progress of PD-1/PD-L1 pathway inhibitor in the immunotherapy of digestive system neoplasm[J]. Chin J Clin Pharmacol Ther,2018,23(8):942-948.(in Chinese)蒙秋华，田婧，覃斐章，等．PD-1/PD-L1通路抑制剂在消化系统肿瘤免疫治疗的研究进展[J]．中国临床药理学与治疗学，2018,23(8):942-948.

[6] GANI F,NAGARAJAN N,KIM Y,et al. Program death 1 immune checkpoint and tumor microenvironment:Implications for patients with intrahepatic cholangiocarcinoma[J]. Ann Surg Oncol,2016,23(8):2610-2617.

[7] YU F,GONG L,MO Z,et al. Programmed death ligand-1,tumor infiltrating lymphocytes and HLA expression in Chinese extrahepatic cholangiocarcinoma patients:Possible immunotherapy implications[J]. Biosci Trends,2019,13(1):58-69.

[8] SABBATINO F,VILLANI V,YEARLEY JH,et al. PD-L1 and HLA Class I antigen expression and clinical course of the disease in intrahepatic cholangiocarcinoma[J]. Clin Cancer Res,2016,22(2):470-478.

[9] BANG YJ,DOI T,BRAUD FD,et al. Safety and efficacy of pembrolizumab(MK-3475)in patients(pts)with advanced biliary tract cancer:Interim results of KEYNOTE-028[J]. Eur J Cancer,2015,51(3):s112.

[10] SUI M,LI Y,WANG H,et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1blockade[J]. J Immunother Cancer,2019,7(1):125.

[11] ASAOKA Y,IJICHI H,KOIKE K. PD-1 Blockade in tumors with mismatch-repair deficiency[J]. N Engl J Med,2015,373(20):1979.

[12] MOU H,YU L,LIAO Q,et al. Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1expression:A case report[J]. BMC Cancer,2018,18(1):1105.

[13] PYO JS,KANG G,KIM JY. Prognostic role of PD-L1 in malignant solid tumors:A meta-analysis[J]. Int J Biol Markers,2017,32(1):e68-e74.

[14] LIU RC,CONSUEGRA G,CHOU S,et al. Vitiligo-like depigmentation in oncology patients treated with immunotherapies for nonmelanoma metastatic cancers[J]. Clin Exp Dermatol,2019,44(6):643-646.

[15] ZHAO R,CHINAI JM,BUHL S,et al. HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell function[J]. Proc Natl Acad Sci U S A,2013,110(24):9879-9884.

[16] JING CY,FU YP,YI Y,et al. HHLA2 in intrahepatic cholangiocarcinoma:An immune checkpoint with prognostic significance and wider expression compared with PD-L1[J]. J Immunother Cancer,2019,7(1):77.

[17] GARNELO M,TAN A,HER Z,et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut,2017,66(2):342-351.

[18] GOEPPERT B,FRAUENSCHUH L,ZUCKNICK M,et al. Prognostic impact of tumour-infiltrating immune cells on biliary tract cancer[J]. Br J Cancer,2013,109(10):2665-2674.

[19] TRAN E,TURCOTTE S,GROS A,et al. Cancer immunotherapy based on mutation-specific CD4+T cells in a patient with epithelial cancer[J]. Science,2014,344(6184):641-645.

[20] KAN N,YOSHIKAWA K,MATSUSHITA N,et al. The case of a patient with peritoneal metastasis from cholangiocarcinoma who responded to adoptive immunotherapy and cetuximab[J]. Gan To Kagaku Ryoho,2013,40(12):1759-1761.

[21] SHIMIZU K,KOTERA Y,ARUGA A,et al. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma[J]. J Hepatobiliary Pancreat Sci,2012,19(2):171-178.

[22] JIN K. DC-CIK cells immunotherapy study on the immune function of patients with bile duct carcinoma after surgery[D].Suzhou:Soochow University,2013.(in Chinese)金奎．DC-CIK细胞免疫治疗对胆管癌术后患者免疫功能影响的研究[D]．苏州:苏州大学，2013.

[23] LEPISTO AJ,MOSER AJ,ZEH H,et al. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors[J]. Cancer Ther,2008,6(B):955-964.

[24] KOBAYASHI M,SAKABE T,ABE H,et al. Dendritic cell-based immunotherapy targeting synthesized peptides for advanced biliary tract cancer[J]. J Gastrointest Surg,2013,17(9):1609-1617.

[25] KOIDO S,KAN S,YOSHIDA K,et al. Immunogenic modulation of cholangiocarcinoma cells by chemoimmunotherapy[J].Anticancer Res,2014,34(11):6353-6361.

[26] LIN Z,XIE QL,LI SY,et al. Advanced of HER-2/neu epitope anti-tumor vaccine[J]. Chin J Clin Pharmacol Ther,2019,24(9):1046-1052.(in Chinese)林忠，谢群莉，李胜英，等．HER-2/neu表位肿瘤疫苗研究进展[J]．中国临床药理学与治疗学，2019,24(9):1046-1052.

[27] JUNKING M,GRAINOK J,THEPMALEE C,et al. Enhanced cytotoxic activity of effector T-cells against cholangiocarcinoma by dendritic cells pulsed with pooled mRNA[J]. Tumour Biol,2017,39(10):1010428317733367.

[28] ARUGA A,TAKESHITA N,KOTERA Y,et al. Long-term vaccination with multiple peptides derived from cancer-testis antigens can maintain a specific T-cell response and achieve disease stability in advanced biliary tract cancer[J]. Clin Cancer Res,2013,19(8):2224-2231.

[29] ARUGA A,TAKESHITA N,KOTERA Y,et al. Phase I clinical trial of multiple-peptide vaccination for patients with advanced biliary tract cancer[J]. J Transl Med,2014,12(61):61.

施引文献

资源附件(0)

访问统计